| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 14 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 890.4K | $41.34M | - | |
| CEO | 875.0K | $40.62M | - | |
| Other | 740.2K | $34.36M | - | |
| 10% | 245.7K | $11.41M | -281,408 | |
| COO | 215.0K | $9.98M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2024 | Patel Anish54 | Chief Operating Officer | Sell | 4,875 | $15.64 | $76,238.66 | -39.5% | +35.5% | +38.9% | |
| Feb 29, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sale+OE | 12,000 | $16.42 | $197,006.30 | -86.9% | +33.6% | +30.4% | |
| Feb 27, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 3,250 | $16.97 | $55,162.90 | -100% | +31.3% | +14.7% | |
| Feb 26, 2024 | Kintz Samuel51 | President And CEO | Sale+OE | 12,000 | $16.89 | $202,653.44 | -73.3% | +32.2% | +14.6% | |
| Feb 15, 2024 | Heyman Richard A.74 | Director | Sell | 1,270 | $17.42 | $22,117.43 | -0.9% | +38.7% | +25.3% | |
| Feb 14, 2024 | 5am Partners Vi, LLC | 10% Owner | Sell | 825,000 | $14.90 | $12,292,500.00 | -17.7% | +39.0% | +25.2% | |
| Feb 6, 2024 | Patel Anish54 | Chief Operating Officer | Sell | 4,875 | $15.11 | $73,658.33 | -28.3% | +45.7% | +44.6% | |
| Jan 31, 2024 | 5am Partners Vi, LLC | 10% Owner | Sell | 500,000 | $15.00 | $7,500,000.00 | -9.7% | +10.8% | +35.5% | |
| Jan 30, 2024 | Heyman Richard A.74 | Director | Sell | 1,270 | $16.41 | $20,839.56 | -0.9% | +9.3% | +28.1% | |
| Jan 29, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sale+OE | 12,000 | $15.85 | $190,256.40 | -100% | +7.5% | +27.1% |